Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Agustin Melian Biography and Net Worth

Insider of AlloVir

Dr. Melian is AlloVir’s Chief Medical Officer & Head of Global Medical Sciences.
Prior to joining AlloVir, Dr. Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals. During his tenure there, the company achieved record timelines across clinical development including Ultomiris (a >500 patients rare disease development program fully executed from Investigational New Drug (IND) application to filing in

Dr. Melian has a background in DNA transcription and repair. Prior to his industry work, he practiced medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. Dr. Melian graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.

What is Agustin Melian's net worth?: The estimated net worth of Agustin Melian is at least $394,108.63 as of July 2nd, 2021. Dr. Melian owns 498,304 shares of AlloVir stock worth more than $394,109 as of April 23rd. This net worth estimate does not reflect any other assets that Dr. Melian may own. Learn More about Agustin Melian's net worth.
How do I contact Agustin Melian?: The corporate mailing address for Dr. Melian and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Agustin Melian's contact information.
Has Agustin Melian been buying or selling shares of AlloVir?: Agustin Melian has not been actively trading shares of AlloVir during the past quarter. Most recently, Agustin Melian sold 18,689 shares of the business's stock in a transaction on Monday, October 4th. The shares were sold at an average price of $23.91, for a transaction totalling $446,853.99. Learn More on Agustin Melian's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 37 times. They sold a total of 180,585 shares worth more than $275,701.48. The most recent insider tranaction occured on April, 2nd when General Counsel Edward Miller sold 368 shares worth more than $283.36. Insiders at AlloVir own 40.0% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 4/2/2024.

Agustin Melian Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2021	Sell	18,689	$23.91	$446,853.99
9/28/2021	Sell	3,750	$24.12	$90,450.00
9/15/2021	Sell	800	$24.03	$19,224.00
7/2/2021	Sell	18,586	$19.99	$371,534.14	498,304
4/5/2021	Sell	18,212	$23.89	$435,084.68
3/22/2021	Sell	3,750	$25.97	$97,387.50	516,516

Agustin Melian Buying and Selling Activity at AlloVir

AlloVir Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $0.79

$0.76

$0.83

50 Day Range

MA: $0.74

$0.67

$0.80

2 Week Range

Now: $0.79

$0.62

$6.12

Volume

280,504 shs

Average Volume

1,187,760 shs

Market Capitalization

$90.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86